Alnylam Pharmaceuticals (GB:0HD2)

Alnylam Pharma (0HD2) Financial Statements


Alnylam Pharma Financial Overview

Alnylam Pharma's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Alnylam Pharma is scheduled to report earnings on August 1, 2023, and the estimated EPS forecast is $-1.51. See an overview of income statement, balance sheet, and cash flow financials.
Mar 23Dec 22Sep 22Jun 22Mar 22
Income Statement-
Total Revenue$ 319.29M$ 599.42M$ 264.31M$ 224.82M$ 213.26M
Gross Profit$ 264.42M$ 548.16M$ 223.19M$ 184.01M$ 177.63M
EBIT$ -162.06M$ 88.29M$ -364.86M$ -232.06M$ -196.99M
EBITDA$ -150.05M$ 98.87M$ -344.21M$ -201.51M$ -187.53M
Net Income Common Stockholders$ -174.10M$ 56.90M$ -405.92M$ -277.40M$ -240.34M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.07B$ 2.19B$ 2.27B$ 2.11B$ 2.24B
Total Assets$ 3.39B$ 3.55B$ 3.54B$ 3.33B$ 3.43B
Total Debt$ 1.32B$ 1.32B$ 1.32B$ 990.98M$ 995.39M
Net Debt$ -750.33M$ -872.16M$ -941.45M$ -1.12B$ -1.24B
Total Liabilities$ 3.65B$ 3.55B$ 3.60B$ 3.15B$ 3.03B
Stockholders Equity$ -259.24M$ -158.22M$ -67.64M$ 176.04M$ 401.17M
Cash Flow-
Free Cash Flow$ -180.37M$ -153.61M$ -131.79M$ -138.87M$ -189.05M
Operating Cash Flow$ -166.47M$ -131.98M$ -115.28M$ -122.82M$ -171.19M
Investing Cash Flow$ -76.22M$ -139.91M$ 313.89M$ 142.79M$ -147.42M
Financing Cash Flow$ 46.37M$ 63.44M$ 297.02M$ 30.34M$ 34.96M
Currency in USD

Alnylam Pharma Earnings and Revenue History

Alnylam Pharma Debt to Assets

Alnylam Pharma Cash Flow

Alnylam Pharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis